Warren Huff, Reata CEO

August 10, 2020 05:07 PM EDTUpdated August 11, 07:07 AM

Reata suggests Friedreich's ataxia program could be delayed, sending stock plunging

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges